Key result
Baseline statin use was not associated with an increased risk of overall serious adverse events among patients without baseline cardiovascular disease randomized to standard blood pressure management.
Why the study?
Does statin use at baseline increase the risk of serious adverse events among participants in the SPRINT trial?
Cohort (n=3,746)
Does statin use at baseline increase the risk of serious adverse events among participants in the SPRINT trial?
Secondary analysis of the SPRINT trial suggests that baseline statin use is generally not associated with increased serious adverse events, except potentially among higher-risk patients on intensive blood pressure therapy.
Answers are grounded in this paper and cite their sources.
Reassures on statin safety with standard BP management; leaves open interactions with intensive control in higher-risk subgroups.
BACKGROUND: Real-world evidence of statin side effects is potentially biased because statin use is neither randomized nor unblinded. An innovative study design can mitigate these biases. For example, in the recent ASCOT-LLA trial, patient-reported adverse events such as muscle pain and weakness were higher in the non-randomized and non-blinded setting than in the randomized, blinded setting. Less optimally, secondary re-analysis of clinical trials in which statin use is recorded and in which serious adverse events (SAEs) are adjudicated may be conducted. OBJECTIVE: The objective of this study was to evaluate SAEs by statin use at baseline among participants in the SPRINT blood pressure (BP) management trial. METHODS: Unadjusted overall SAE and treatment-related SAE rates by statin use as well as adjusted hazard ratios for statin use were computed in four cohorts [by baseline clinical cardiovascular disease (CVD), by intervention arm]. RESULTS: Statin use at baseline was not associated with higher overall or treatment-related SAE rates among (1) those without pre-existing CVD, regardless of BP arm, nor among (2) those randomized to standard BP management, regardless of pre-existing CVD. Among higher risk patients with existing clinical CVD randomized to intensive BP management, a small but significant increase in overall SAE rate was found among those taking statin at baseline. CONCLUSIONS: In SPRINT, generally statin use was not associated with increased risk of reporting SAEs. Only statin use by higher risk patients was associated with more overall SAEs. Confounding by clinical CVD and the polytherapy of intensive BP management may explain this.
No takes yet. Share an insight, caveat, or question.
Marco D. Huesch (2017) conducted a cohort in Hypertension (n=3,746). Statin use at baseline vs. No statin use at baseline was evaluated on Overall serious adverse events (HR 0.97, 95% CI 0.85-1.09, p=0.58). Baseline statin use was not associated with an increased risk of overall serious adverse events among patients without baseline cardiovascular disease randomized to standard blood pressure management.
Synapse has enriched 10 related papers. Consider them for comparative context: